diosmetine

Small moleculeexperimental

Diosmin is a flavone indicated for the treatment of venous disease i.e., chronic venous insufficiency (CVI) including spider and varicose veins, leg swelling (edema), stasis dermatitis and venous ulcers. Diosmin is also used as a stand-alone or surgical adjunctive therapy in hemorrhoidal disease. There are extensive clinical trials that show diosmin improves all stages of venous disease including venous ulcers and improves quality of life. Diosmin prolongs the vasoconstrictor effect of norepinephrine on the vein wall, increasing venous tone, and therefore reducing venous capacitance, distensibility, and stasis. This increases the venous return and reduces venous hyperpressure present in patients suffering from CVI. Diosmin improves lymphatic drainage by increasing the frequency and intensity of lymphatic contractions, and by increasing the total number of functional lymphatic capillaries. Furthermore, diosmin with hesperidine decreases the diameter of lymphatic capillaries and the intralymphatic pressure. Diosmin reduces the expression of endothelial adhesion molecules (ICAM1, VCAM1), and inhibits the adhesion, migration, and activation of leukocytes at the capillary level. This leads to a reduction in the release of inflammatory mediators, principally oxygen free radicals, and prostaglandins (PGE2, PGF2a). Diosmin is currently a prescription medication in some European countries (under the Dio-PP, Venotec, Daflon etc. tradenames), and is sold as a nutritional supplement in the United States. — NCATS

Clinical trial activity

34 trials · 31 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
14
Phase 3
12
Phase 4
6

Earliest trial started Jan 1, 2012 (NCT01532882)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2014

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Mechanism of action

  • Unspecified targetOTHER

    Unknown

    Diosmin (diosmetin 7-O-rutinoside), is a natural flavone glycoside which is indicated for the treatment of hemorrhoids, lymphedema and varicose veins. It is well known to possess antiinflammatory, antioxidant, antimutagenic and anti-hyperlipidemic properties. It has been reported that diosmin significantly increased the transport of digoxin and cellular accumulation of rhodamine-123 in Caco-2 cells by inhibition of P-gp-mediated efflux. It has also been reported a protective mechanisms on LPS-induced lung injury through inhibition of T cell receptors, pro-inflammatory cytokines and NF-kB activation.

Chemistry & pharmacology

Loading structure…

SMILES

COC1=C(O)C=C(C=C1)C2=CC(=O)C3=C(O2)C=C(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)C=C3O
Mol. weight
608.5447 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucoside
  • 3',5,7-trihydroxy-4'-methoxyflavone 7-rhamnoglucoside
  • 3',5,7-trihydroxy-4'-methoxyflavone-7-rutinoside
  • 3',5,7-trihydroxy-4'-methoxyflavone-7-rutinoside
  • barosmin
  • daflon
  • daflon
  • diosmetin
  • diosmetin
  • diosmetin 7-neohesperidoside
  • diosmetin 7-neohesperidoside
  • diosmetin 7-o-rutinoside
  • diosmetin 7-o-rutinoside
  • diosmetine
  • diosmetine
  • diosmetine
  • diosmil
  • diosmin
  • diosmin
  • diosmin
  • diosmin
  • diosmin
  • diosmin
  • diosmin
  • diosmin
  • diosmine
  • diosmine
  • diosmine
  • diovenor
  • diovenor
  • flebosmil
  • flebosten
  • vasculera

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07176182Phase 2Nov 1, 2025Sun Yat-Sen University
NCT07185386N/AMay 28, 2025Ekalab S.r.l.
NCT07300735N/AMar 1, 2025Alexandria University
NCT06811220Phase 3Jan 27, 2025Alexandria University
NCT06256575N/ADec 15, 2024KGK Science Inc., Primus Pharmaceuticals
NCT07293767N/ANov 16, 2024Ain Shams University
NCT06546111Phase 1/Phase 2 (Phase 2)Oct 1, 2024Sadat City University
NCT06584799Phase 3Sep 30, 2024Pirogov Russian National Research Medical University
NCT06560294N/AAug 17, 2024Tanta University
NCT06125002Phase 1Jan 31, 2024Universidade Estadual de Londrina, Universidade Norte do Paraná
NCT06083935Phase 4Nov 1, 2023Ain Shams University
NCT05756179Phase 3Jul 18, 2023Alexandria University
NCT05942547Phase 3Jul 10, 2023Tanta University
NCT06367166N/AApr 1, 2023Ryazan State Medical University
NCT05626166Phase 3Nov 30, 2022Tanta University
NCT05670457Phase 3Jun 30, 2022Tanta University
NCT05243706Phase 3Mar 1, 2022Ain Shams University
NCT05158192Phase 1Nov 4, 2021Grunenthal
NCT04358497Phase 4Oct 1, 2020Centro Cardiovascular Universitario, Hospital de Clínicas Dr. Manuel Quintela, Hospital Pereyra Rossell, Montevideo, University of the Republic, Uruguay
NCT04933591N/ASep 1, 2020Pirogov Russian National Research Medical University
Showing 20 of 34 trials
Page 1 / 2

Organizations

Research & Development (31)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tanta UniversityAcademic/Hospital5532020
Ain Shams UniversityAcademic/Hospital4442015
Alexandria UniversityAcademic/Hospital3322023
Pirogov Russian National Research Medical UniversityAcademic/Hospital3332018
Primus PharmaceuticalsFor profit3312015
Opera CROFor profit2022016
Ryazan State Medical UniversityAcademic/Hospital2222019
ServierFor profit2022012
Albert Einstein Israelite HospitalAcademic/Hospital1012017
Benha UniversityAcademic/Hospital1112014
Centro Cardiovascular UniversitarioAcademic/Hospital1012020
Ekalab S.r.l.For profit1112025
Fundação Educacional Serra dos ÓrgãosAcademic/Hospital1112017
Giellepi S.p.AFor profit1112019
GrunenthalFor profit1112021
Hospital de Clínicas Dr. Manuel QuintelaAcademic/Hospital1112020
Hospital Pereyra Rossell, MontevideoAcademic/Hospital1012020
KGK Science Inc.For profit1012024
Laboratoire Innotech InternationalFor profit1112012
Laboratório Teuto Brasileiro S/AFor profit1112012
31 organizations
Page 1 / 2